Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for SECUKINUMAB
- Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR
- Phase I Randomized, Open-label, Parallel-controlled, Pharmacokinetic and Safety Study of BR201 Injection Versus Cosentyx in Healthy Male Subjects
- Topical Pentoxifylline; Metformin Versus Betamethasone in the Treatment of Alopecia Areata.
- Outcome of Treatment With Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis at Tertiary Care Hospital.
- Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR)
- Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy
- Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy
- Secukinumab in Active Non-segmental Vitiligo
- A Study of Secukinumab to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved Remission
- Study of Efficacy and Safety and of AIN457/Secukinumab in Patients With Rotator Cuff Tendinopathy
- The Clinical Efficacy and the Changes of Immune Cells Subsets With Bioagents in Ankylosing Spondylitis Patients
- A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 4
- Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical Remission
- A Study Evaluating the Efficacy of Secukinumab 300mg in Chinese Adults With Active Ankylosing Spondylitis
- Open-label Extension Study of Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Lupus Nephritis
- COVID-19 VaccinE Response in Rheumatology Patients
- Scientific Substantiation and Assessment of the Effectiveness of Pathogenetic Methods of Therapy for Congenital Ichthyosis in Children
- An Efficacy Study of Secukinumab In Enthesitis of Psoriatic Arthritis Patients
- EBIO - Enthesitis Biopsy Study
- A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED)
- Efficacy and Safety Study of Secukinumab in Chinese Participants With Non-radiographic Axial Spondyloarthritis
- Study of Efficacy and Safety of Secukinumab in Chinese Subjects With Active PsA Compared to Placebo.
- Comparative Study to Evaluate the Pharmacokinetics of BAT2306 vs Cosentyx® in Healthy Subjects
- Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis
- A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 1
- A Study to Evaluate the Efficacy and Safety of Secukinumab in Adult Patients With Skin Types IV-VI With Moderate to Severe Plaque Psoriasis
- Open Label Study of the Effects of Secukinumab on Nail Psoriasis and Non-Invasive Measures of Enthesitis (Phase IV)
- Methotrexate Versus Secukinumab Safety in Psoriasis Patients With Metabolic Syndrome
- Oral Chinese Herbal Medicine Concurrent With Secukinumab for Severe Plaque Psoriasis
- COLchicine Versus Ruxolitinib and Secukinumab In Open Prospective Randomized Trial
- Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis
- PoC Study to Evaluate the Efficacy and Safety of Secukinumab 300 mg in Patients With Lichen Planus
- Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum
- Outcomes With Treatment and Withdraw of Secukinumab in Patients With Plaque Psoriasis
- Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic Arthritis
- Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis
- Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa
- PsA T2T Statin Trial on Carotid and Coronary Atherosclerosis
- Study to Demonstrate the Efficacy, Safety and Tolerability of an Intravenous Regimen of Secukinumab Compared to Placebo in Subjects With Active axSpA
- A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or Ixekizumab
- A Study to Assess the Safety and Efficacy of Secukinumab in Alleviating Symptoms of Discoid Lupus Erythematosus
- Secukinumab for NLD (Cosentyx) in Patients With Necrobiosis Lipoidica Diabeticorum (NLD)
- An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA)
- A Placebo-controlled Phase 2 Trial to Investigate the Safety and Efficacy of Secukinumab in Giant Cell Arteritis
- Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS)
- This is a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS).
- Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis
- Treat-to-target With Secukinumab in Axial Spondyloarthritis
- PsA Secukinumab XCT Structural Progression Study
- Study of Efficacy and Safety of Secukinumab 2 mL Auto-injector (300 mg) in Subjects With Moderate to Severe Plaque Psoriasis
- Investigation of Efficacy of Secukinumab in Patients With Moderate to Serve Atopic Dermatitis
- A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
- A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)
- Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis
- Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis
- Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis
- Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psoriasis Patients With Concomitant Metabolic Syndrome
- Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed IL-17A Therapies
- A Phase 2b Study of the Efficacy, Safety, and Tolerability of M1095 (Sonelokimab) in Subjects With Moderate to Severe Psoriasis
- Mechanism of Action of Anti-IL17 Therapy in Peripheral Spondyloarthritis
- Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing Spondylitis
- Study of Efficacy, Safety and Tolerability of AIN457 in Patients With Active Overuse Tendinopathy
- Cosentyx (Secukinumab) for the Treatment of Adult Onset Pityriasis Rubra Pilaris
- Secukinumab Therapy for the Treatment of Moderate to Severe Plaque Psoriasis With Response Monitoring Using Optical Coherence Tomography (OCT).
- SKIPPAIN - Speed of Onset of SecuKinumab-Induced Relief From Pain in Patients With AxIal SpoNdyloarthritis
- Safety and Efficacy of Secukinumab in Mild Psoriasis
- A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis
- Open Label Study to Assess the Effect of Secukinumab in Moderate to Severe Papulopustular Rosacea
- Study of Efficacy and Safety of Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
- The Efficacy and Safety of Secukinumab in Patients With Ichthyoses
- Secukinumab Safety and Efficacy in Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-related Arthritis (ERA)
- Study of the Efficacy of Early Intervention With Secukinumab 300 mg s.c. Compared to Narrow-band UVB in Patients With New-onset Moderate to Severe Plaque Psoriasis
- Study of Efficacy and Safety of Secukinumab in Patients With Ankylosing Spondylitis
- Effect of Secukinumab in the Treatment of Psoriatic Arthritis
- Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
- Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo
- Assessment of Efficacy and Safety of Secukinumab in Adult Patients in Turkish Population
- Anti-IL-17 a New Treatment for Contact Dermatititis
- Study of Efficacy and Safety of Secukinumab in Psoriatic Arthritis and Axial Spondyloarthritis Patients With Active Enthesitis Including One Achilles Tendon Site
- Study to Examine the Clinical Efficacy and the Nonsteroidal Anti-inflammatory Drug (NSAID)-Sparing Effect of Secukinumab Over 16 Weeks in Patients With Ankylosing Spondylitis
- A Study to Evaluate Clear Skin Effect on Quality of Life in Patients With Plaque Psoriasis.
- Study of Efficacy and Safety of Secukinumab in Japanese Patients With Active Ankylosing Spondylitis
- Study of Secukinumab With 2 mL Pre-filled Syringes
- Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma Gangrenosum
- Study of the Efficacy and Safety of Secukinumab in Participants With Active Psoriatic Arthritis With Axial Skeleton Involvement
- Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis
- Study to Evaluate the Effect of Secukinumab Compared to Placebo on Aortic Vascular Inflammation in Subjects With Moderate to Severe Plaque Psoriasis
- Study of Power Doppler Ultrasound (PDUS) to Measure Response of Secukinumab Treatment in Patients With Active Psoriatic Arthritis (PsA)
- Investigate Effect of Secukinumab on the PK of Midazolam in Patients With Mod to Sev Plaque Psoriasis
- A Study of Secukinumab for the Treatment of Alopecia Areata
- Study to Evaluate Psoriasis Severity and Its Psychosocial Impact Using the Simplified Psoriasis Index (SPI), as Well as Long-term Safety, Tolerability and Efficacy of Secukinumab Administered Subcutaneously in Patients With Moderate to Severe Psoria
- Secukinumab for Treatment of Atopic Dermatitis
- Immunologic Response to Secukinumab in Plaque Psoriasis
- Evaluation of Cardiovascular Risk Markers in Psoriasis Patients Treated With Secukinumab
- Open-label Study of Subcutaneous Secukinumab to Evaluate Efficacy and Safety in Patients With Plaque Psoriasis Who Had Inadequate Response to Cyclosporine A
- Psoriasis-Arthritis & Bone Program
- Study of Secukinumab Compared to Fumaderm® in Adults With Moderate to Severe Psoriasis.
- Secukinumab Dosage Optimisation in Partial Responders With Moderate to Severe Plaque-type Psoriasis
- Effects of Treatment With Biological Agents on Vascular and Cardiac Function in Psoriasis
- Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis
- Study of Secukinumab in Patients With Newly-diagnosed Type 1 Diabetes Mellitus
- 16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients
- Palmoplantar Pustular Psoriasis Efficacy and Safety wIth Secukinumab
- Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis
- Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
- Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis
- 16 Week Efficacy and 5 Year Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis
- 4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
- Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)
- First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks
- Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab
- Distribution of Secukinumab (AIN457) Into Dermal Interstitial Fluid After a Single Subcutaneous Administration of 300 mg
- Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients
- Safety, Tolerability, and Efficacy of AIN457 in Patients With Uncontrolled Asthma
- A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
- Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis
- Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens
- Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)
- Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year
- Efficacy, Safety and Tolerability of Secukinumab in Patients With Rheumatoid Arthritis Taking Methotrexate
- Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis
- 16 Week Efficacy and 2 Year Long Term Safety and Efficacy of Secukinumab in Patients With Active Ankylosing Spondylitis
- AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
- Efficacy, Safety and Tolerability of AIN457 in Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX)
- Multiple-loading Dose Regimen Study in Patients With Chronic Plaque-type Psoriasis
- Safety and Efficacy of AIN457 in Noninfectious Uveitis
Clinical trials list
click for details